BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30153955)

  • 1. Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
    Xu S; Zhou C; Liu R; Zhu Q; Xu Y; Lan F; Zha X
    Bioorg Med Chem; 2018 Sep; 26(17):4871-4880. PubMed ID: 30153955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
    Zhou C; Kang D; Xu Y; Zhang L; Zha X
    Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
    Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y
    J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
    Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
    Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
    Li L; Li R; Wang Y
    Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
    Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
    Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
    Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
    Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
    J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.